Merck wins FDA OK for new CMV drug Prevymis, triggering a $122M payday for AiCuris
Five years after bagging the CMV drug letermovir in a $500 million-plus deal with AiCuris, Merck says the FDA has come through with an approval …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
